What are the opening hours?

Monday 9am - 6pm Tuesday 9am - 6pm Wednesday 9am - 6pm Thursday 9am - 6pm Friday 9am - 6pm

Achelois BioPharma

Home
United States
Redwood City, CA
Achelois BioPharma

Achelois BioPharma develops curative, programmable Multivalent Therapeutics to treat cancer, viral i

09/21/2022

According to the American Cancer Society, cancer is the second most common cause of death in the U.S.

Traditional cancer treatments like chemotherapy and radiation have limited efficacy and are enormously toxic. That’s why we have spent years developing nontoxic cancer therapeutics—to give you and your loved ones a better solution.

At Achelois, we discovered genetic-enhancing modifiers (GEMs) that can reprogram tumor-targeting T cells to overcome immune suppression and eliminate cancer. GEMs can be used to program tumor-targeting T cells, including CAR-T cells, TCR-T cells, and TILs (tumor-infiltrated lymphocytes). They can also enable effective T cell therapy for cancer.

Contact us today to learn more about our innovative cancer treatment. https://buff.ly/3v7YIs0

09/15/2022

Interested in partnering with or investing in Achelois BioPharma?

Contact us today to learn more about available opportunities: https://buff.ly/3PngHmx

09/13/2022

Achelois has developed variant-resistant antiviral therapeutics, called Antiviruses, to fight and prevent COVID-19. Using multivalent display technology inspired by viruses themselves, Antiviruses function as virus Velcro and turn one of viruses’ greatest strengths against them. Unlike vaccines and antibody treatments, which constantly have to adapt to changing variants, Antiviruses are variant-resistant and suitable for both prevention and treatment.

Visit our website to learn more: https://buff.ly/3v7YIs0

09/09/2022

In ancient Greek mythology, Achelois (A-khe-LO-iz) is a goddess who provides comfort and healing to those around her. Her name has been translated as “she who washes away pain.” At Achelois BioPharma, we develop curative medicine to wash away the physical, emotional, and financial pains of patients and their loved ones. Our proprietary programmable medicine technologies provide the next generation of medicine with tools to combat cancer and infectious disease and offer hope to people seeking better treatment options.

To learn more about Achelois BioPharma, visit our website: https://achelois.bio/

09/07/2022

Meet Dr. Chen, the founder & CEO of Achelois BioPharma. Before starting Achelois, Dr. Chen was on the faculty at Stanford University School of Medicine. He made pioneering contributions in the fields of immunology, stem cell, cancer, and microRNA biology. He was awarded the Director’s Pioneer Award by the National Institute of Health and Distinguished Young Scholar in Medical Research by the W.M. Keck Foundation.

Visit our website to learn more about Dr. Chen: https://buff.ly/3J6pwio

09/01/2022

According to American Cancer Society, there will be an estimated 1.9 million new cancer cases in 2022. At Achelois, we discovered genetic-enhancing modifiers (GEMs) that can reprogram tumor-targeting T cells to overcome immune suppression and eliminate cancer.

Contact us today to learn more about our innovative cancer treatment. https://achelois.bio/contact

08/30/2022

Meet Dr. Cassian Yee, a member of the Scientific Advisory Board at Achelois BioPharma. Dr. Yee is a pioneer in adoptive cell transfer (ACT) immunotherapy, which involves taking anti-cancer T cells from patients and then enhancing their anti-tumor capabilities before putting them back into patients. He pioneered several seminal first-in-human studies using a well-defined, uniform population of ex vivo expanded antigen-specific T cells to delineate the requirements for effective immune-based therapies. He helped establish standards for the process, demonstrated that these T cells can confer durable anti-tumor memory, and showed how checkpoint immunotherapy can enhance ACT’s effects.

Visit our website to learn more about Dr. Yee and the rest of the team: https://buff.ly/3J6pwio

08/25/2022

At Achelois, we discovered genetic-enhancing modifiers (GEMs) that can reprogram tumor-targeting T cells to overcome immune suppression and eliminate cancer. GEMs can be used to program tumor-targeting T cells, including CAR-T cells, TCR-T cells, and TILs (tumor-infiltrated lymphocytes). They can also enable effective T cell therapy for cancer.

Contact us today to learn more about our innovative cancer treatment. https://buff.ly/3v7YIs0

08/23/2022

Meet Dr. Richard Colonno, a member of the Scientific Advisory Board at Achelois BioPharma. Dr. Colonno is an internationally recognized drug developer with over 40 years of experience in antiviral drug discovery and development. He recently served as Chief Science Officer at Assembly Bio and Presidio Pharmaceuticals, where he was responsible for providing scientific strategies, oversight, and direction for virology programs pursued, in addition to discovery, early development, and clinical support of novel antiviral agents.

Visit our website to learn more about Dr. Colonno and the rest of the team: https://buff.ly/3J6pwio

08/17/2022

We recently launched our new website designed to help you better access our resources on programmable medicine and more.

Check it out and let us know what you think! https://achelois.bio/

08/16/2022

We recently rebranded Achelois BioPharma with a new logo that symbolizes how we develop curative medicine to wash away the physical, emotional, and financial pains of patients and their loved ones.

Let us know what you think of the new brand!

08/11/2022

Meet Dr. Padmanee Sharma, a member of the Scientific Advisory Board at Achelois BioPharma. Dr. Sharma is a renowned physician-scientist who is a pioneer of immune checkpoint therapy, leading some of the earliest clinical trials in the field. She currently serves as the scientific director of James P Allison Institute, associate vice president of Immunobiology, and professor of Genitourinary Medical Oncology with a dual appointment as professor of Immunology at MD Anderson. Dr. Sharma also holds the T.C. and Jeanette D. Hsu Endowed Chair in Cell Biology and is scientific director of MD Anderson’s immunotherapy platform.

Visit our website to learn more about Dr. Sharma and the rest of the team: https://buff.ly/3J6pwio

Address

3698 Haven Avenue , Ste. A
Redwood City, CA
94063

Opening Hours

Monday	9am - 6pm
Tuesday	9am - 6pm
Wednesday	9am - 6pm
Thursday	9am - 6pm
Friday	9am - 6pm

Website

https://achelois.bio/

Alerts

Be the first to know and let us send you an email when Achelois BioPharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your business to be the top-listed Engineering Company in Redwood City?